Why Is Medicus Pharma's Study Raising Global Concerns?

2 min read | December 02, 2024 09:49 AM EST | By Team Kalkine Media

Why Is Medicus Pharma's Study Raising Global Concerns? — Image source: Shutterstock

Phase 2 Study Overview

The ongoing trial, SKNJCT-003, assesses the investigational product D-MNA for its efficacy and safety at two dose levels. The study follows a double-blind, randomized, placebo-controlled format and is currently being conducted at nine clinical sites across the United States. An interim data analysis is expected in 2025, with findings to be submitted to the US Food and Drug Administration. Medicus Pharma aims to align its clinical pathway and explore transitioning the trial into a pivotal stage.

Collaboration with Swanielle

The agreement with Swanielle, effective from December 2024, focuses on enhancing the clinical program by expanding its reach into Southeast Asia. This collaboration aims to gather additional efficacy and safety data, essential for strengthening the trial’s overall framework. Swanielle’s role includes facilitating connections with potential pharmaceutical partners to support the study’s progress.

Historical Context and Future Plans

The SKNJCT-003 trial builds on Medicus Pharma’s earlier Phase 1 study, SKNJCT-001, completed in 2021. This initial study confirmed the safety and tolerability of D-MNA. The current expansion plans highlight the company’s efforts to advance its non-invasive treatment options for BCC, with a potential shift toward a pivotal clinical trial.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.